Ikena Oncology (NASDAQ:IKNA – Get Free Report) and Kiromic BioPharma (NASDAQ:KRBP – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Valuation and Earnings
This table compares Ikena Oncology and Kiromic BioPharma”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Ikena Oncology | $1.84 million | 44.49 | -$68.17 million | ($1.58) | -1.08 |
Kiromic BioPharma | N/A | N/A | -$20.95 million | ($9.90) | -0.14 |
Kiromic BioPharma has lower revenue, but higher earnings than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
Risk and Volatility
Ikena Oncology has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.
Profitability
This table compares Ikena Oncology and Kiromic BioPharma’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Ikena Oncology | N/A | -40.71% | -34.40% |
Kiromic BioPharma | N/A | N/A | -188.53% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Ikena Oncology and Kiromic BioPharma, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Ikena Oncology | 0 | 1 | 2 | 0 | 2.67 |
Kiromic BioPharma | 0 | 0 | 0 | 0 | N/A |
Ikena Oncology presently has a consensus target price of $3.00, suggesting a potential upside of 76.47%. Given Ikena Oncology’s higher probable upside, equities analysts clearly believe Ikena Oncology is more favorable than Kiromic BioPharma.
Summary
Ikena Oncology beats Kiromic BioPharma on 6 of the 11 factors compared between the two stocks.
About Ikena Oncology
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
About Kiromic BioPharma
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.